Neuromodulation in eating disorders and obesity: A promising way of treatment? by Jáuregui-Lobera, I. & Martínez-Quiñones, J.V.
© 2018 Jáuregui-Lobera and Martínez-Quiñones. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Neuropsychiatric Disease and Treatment 2018:14 2817–2835
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2817
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/NDT.S180231
Neuromodulation in eating disorders and obesity: 
a promising way of treatment?
ignacio Jáuregui-Lobera1 
José v Martínez-Quiñones2
1Department of Molecular Biology 
and Biochemical engineering, 
University of Pablo de Olavide of 
Seville, Seville, Spain; 2Department 
of Neurosurgery, Mutua de 
Accidentes de Zaragoza (Servicio de 
Neurocirugía), Zaragoza, Spain
Abstract: Neuromodulation can affect the functioning of the central nervous system (CNS), 
and emotional/eating behavior is an exciting facet of that functioning. Therefore, it would be 
possible to offer an alternative (or complement) treatment to psychotropic medications and 
different psychological and nutritional approaches to both eating disorders (EDs) and obe-
sity. Although there are a number of publications in these areas, a systematic review has not 
been conducted to date. Abstracts, letters, conference reports, dissertations, and reviews were 
excluded. Clinical trials and controlled human clinical trials were filtered and included in this 
study. Articles included were based on the population suffering from anorexia nervosa, bulimia 
nervosa, binge ED, overweight, and obesity. No restrictions were placed on the sample size. 
Only trials investigating the effect of neuromodulation by means of deep brain stimulation 
(DBS), transcranial direct current stimulation (tDCS), and transcranial magnetic stimulation 
(TMS) were included. The following databases were used to conduct the search: MEDLINE/
PubMed, PsycINFO, PsycArticles, and Cochrane (Search Trials, CENTRAL). Study selection 
was performed following the PRISMA process (PRISMA 2009 Checklist). The total number 
of participants in all the trials was 562 (DBS, 25; tDCS, 138; TMS, 399; range, 3–90; median, 
23.5). As a result, 50% of the studies had samples of between 14 and 38 participants. Neuro-
modulation in ED seems to have certain clinical potential, and therefore, this is a promising area 
for further research. Developments in ED neuromodulation will be linked to neuroimaging to 
identify potential stimulation targets and possible biomarkers of treatment response. To date, 
TMS and/or direct current stimulation (DCS) is not the first-line treatment yet, but it could 
become a preferred option of treatment in the future. Further studies should avoid small sample 
sizes and the use of different methodologies. Currently, neuromodulation techniques are in the 
experimental phase, and they are not an evidence-based treatment for ED.
Keywords: deep brain stimulation, transcranial direct current stimulation, transcranial magnetic 
stimulation, anorexia nervosa, bulimia nervosa, obesity
Introduction
Neuromodulation involves the modification of specific neural circuit activity without 
causing damage to the nervous tissue, which implies the recovery of the prior func-
tional state after suspending the stimulus. This technique aims to activate or deactivate 
neural networks by applying an electric current, controllable with respect to frequency, 
amplitude, and pulse width.1
Neuromodulation has been proposed as an alternative to surgical procedures that 
were being applied in different pathologies. Experimental models have shown that 
the high-frequency electrical stimulation affects the whole neural system, altering its 
metabolism and modifying the production of neurotransmitters and even the protein 
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synthesis. The side effects of surgical electrical stimulation 
are those inherent to the risk of surgery.1
The modern era of neuromodulation was started with the 
study of Benabid et al2 (1987) by means of deep brain stimu-
lation (DBS) for the suppression of tremor in Parkinson’s 
disease. Progress in neuroimaging techniques, with the 
appearance of magnetic resonance and functional imaging, 
along with the improvement of surgical techniques has con-
tributed to a greater development of these techniques and a 
greater precision in their applications.
Neuromodulation, by means of both invasive and non-
invasive interventions, aims to alter the neural activity or 
excitability.3 It induces neuroplastic changes, and therefore, 
it could be used to attempt the reversibility of maladaptive 
neuroplastic changes in the brain, to prevent the development 
of maladaptive neuroplastic changes, or to improve adaptive 
neuroplastic changes occurring in the brain. Neuroplasticity 
is the ability of the neural tissue to reorganize, assimilate, 
and modify the biological, biochemical, and physiological 
mechanisms involved in intercellular communication and to 
adapt to receive stimuli.4,5 This implies modifications of the 
corresponding neural tissue, which includes, among many 
others, axonal regeneration, collateralization, neurogenesis, 
synaptogenesis, and functional reorganization.
These processes are based on signals facilitated or 
inhibited by the nervous system in the presence of differ-
ent neurotransmitters that promote synaptic potentiation or 
depression in both the short and long term.6 These neuro-
chemical mediators produce an increase or a decrease in the 
amplitude of the postsynaptic potential due to a repeated and 
usually rapid action known as tetanization (which can cause 
the mentioned potentiation or depression). This process may 
last for hours or days, partially sustained by molecules called 
“retrograde messengers.” This potentiation or inhibition 
(which may be homosynaptic or heterosynaptic) will affect 
the expression of second messengers such as cyclic AMP, 
either transitorily or permanently.7,8
DBS consists of the implantation of one or more elec-
trodes (connected to a pulse generator) within the cerebral 
parenchyma. Different deep brain structures have been used 
as targets depending on the pathology to be treated. The 
therapeutic effect of DBS is due to a variety of mechanisms, 
modulating the monosynaptic or polysynaptic activity of 
the pathological network. In addition to neuronal changes, 
it causes synaptic and neurotransmitter changes, as well 
as changes in the cerebral blood flow and neuroplasticity 
stimulating neurogenesis. DBS was approved by the Food 
and Drug Administration as a treatment for essential tremor 
in 1997, for Parkinson’s disease in 2002, for primary dystonia 
in 2003, and for obsessive-compulsive disorder in 2009.9,10
Transcranial magnetic stimulation (TMS) is a focal, pain-
less, and noninvasive brain stimulation technique that follows 
the fundamental principles of electromagnetic induction, 
where an electric current in the stimulation coil generates 
a magnetic field. The rate of change in this magnetic field 
induces an electric current flow in the near conductors. Thus, 
when the electric current passes through the stimulation coil 
and when it is placed tangentially on the skull, the generated 
magnetic field induces a parallel intracranial electric current 
of inverse direction that stimulates the cerebral cortex. The 
purpose of this technique is to modulate the excitability of 
the cerebral cortex through the application of brief magnetic 
pulses on the scalp. The adverse effects of TMS are mild and 
usually well tolerated.6,11
Finally, transcranial direct current stimulation (tDCS) is 
another noninvasive way of modulating cortical excitability 
by applying low-amplitude direct electrical stimulation cur-
rents through electrodes arranged on the scalp. This results 
in the neuromodulation of the motor cortex.12
From the psychopathological point of view, the use of 
electric current in the management of diseases is widely 
known, since electroconvulsive therapy (ECT) was first used 
in the 30s of last century. The pathologies that have accumu-
lated more evidence are major depression, drug addiction, 
aggressiveness, and obsessive-compulsive disorder. In these 
cases, neuromodulation has been tried using DBS directed to 
brain structures that are active during the symptomatic phase 
of these pathologies. The aim is to inactivate these structures. 
The most used targets are the anterior arm of internal capsule, 
ventral striatum, subthalamus, inferior thalamic peduncle, 
external pallid globe, amygdala, and posteromedial hypo-
thalamus. Currently, other brain stimulation techniques being 
studied in the treatment of psychiatric diseases are TMS and 
tDCS. Magnetic stimulation has shown a clear efficacy in the 
treatment of depression, and its use is approved by different 
public health agencies.13
With respect to eating disorders (EDs) and overweight/
obesity, neuromodulation might be a useful therapeutic tool 
for several reasons. Traditionally, different psychotherapies, 
several medications, and family support have been used as 
key elements for treating these pathologies. Nevertheless, 
treatment outcomes remain modest, especially for anorexia 
nervosa (AN).14
Neuroimaging techniques have shown that psycho-
therapeutic and pharmacological treatments produce brain 
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Neuromodulation in eating disorders and obesity
been reported to occur in a wide range of brain areas after 
therapy. A relevant problem is that no psychotherapeutic 
or pharmacological treatments target specific brain areas or 
have specific and localized effects.14
In this regard, the idea is that neuromodulation can affect 
the functioning of the central nervous system (CNS) and 
emotional/eating behavior is an exciting facet of that function-
ing. Consequently, it would be possible to offer an alternative 
(or complement) intervention to psychotropic medications 
and different psychological and nutritional approaches.14
Neuroimaging has contributed to the understanding 
of the neural correlates of AN, including comorbidities. 
Thus, the importance of affective brain processing in the 
symptomatology of AN has been reported, suggesting that 
affective regulation and alterations might play key roles in 
the maintenance of symptoms.15 With respect to bulimia 
nervosa (BN), imaging techniques, such as single-photon 
emission computed tomography (SPECT) and positron emis-
sion tomography (PET), usually indicate left frontal cerebral 
hypometabolism in both depressive and bulimic patients. 
These changes of activity in the frontal area might be critical 
for eating behavior.16 Along with BN, binge ED and some 
forms of obesity are characterized by compulsive overeating 
that is often precipitated by food craving. Neuromodulation 
could be relevant to suppress food craving since a growing 
number of studies have sought to directly manipulate dorso-
lateral prefrontal cortex (DLPFC) activation as a means of 
reducing cravings.17 Although overweight/obesity is not ED, 
it is a fact that food craving/overeating is usually a cause for 
obesity. In addition, it has been suggested that extreme weight 
conditions (eg, AN and obesity) have a similar dysfunctional 
executive profile that might play a role in the development 
and maintenance of such disorders.18
Although there are a number of publications in these areas, 
a systematic review has not been conducted to date. At least 
two questions remain: 1) How thoroughly has neuromodula-
tion been tested in controlled human trials? 2) Do the results of 
these trials support the application of neuromodulation to get 
better psychological outcomes and mental health in EDs?
Bearing in mind the efficacy of neuromodulation in dif-
ferent psychopathological disorders, the aim of this work 
was to review the state of knowledge on the use of neuro-
modulation in ED and overweight/obesity. The objective of 
this review was to ascertain whether there is evidence, from 
controlled trials, of an effect of neuromodulation on either 
psychological outcomes or nutritional status in humans. To 
address this question, clinical trials were reviewed systemati-
cally in accordance with PRISMA guidelines.
Materials and methods
Overall, this study observed the methodological steps fol-
lowed by Romijn and Rucklidge in their recent systematic 
review.19
Selection criteria
Selection criteria were defined before searches were com-
pleted. Only articles written or available in English and/or 
Spanish and published in full in peer-reviewed journals were 
included, and abstracts, letters, conference reports, disserta-
tions, and reviews were excluded.
Types of studies
Clinical trials and controlled clinical trials were filtered and 
included in this study.
Types of participants
Only human trials were included. Articles included were 
based on the population suffering from AN, BN, binge ED, 
overweight, and obesity. No restrictions were placed on the 
sample size.
Types of interventions
Only trials investigating the effect of neuromodulation by 
means of DBS, tDCS, and TMS were included.
Outcome measures
Only studies with specific and adequate psychological 
measurements (eg, symptoms of EDs preintervention and 
postintervention) were included.
Searching process
Online databases were searched electronically. In addition, 
relevant studies were searched manually to identify studies 
published up to December 11, 2017.
Databases
Studies published up to December 11, 2017, were searched 
in the following databases: MEDLINE/PubMed, PsycINFO, 
PsycArticles, and Cochrane (Search Trials, CENTRAL).
The following search terms were used: neuromodulation, 
transcranial magnetic stimulation, deep brain stimula-
tion, transcranial direct current stimulation, eating dis-
orders, anorexia nervosa, bulimia nervosa, binge eating 
disorder, and obesity, as well as the corresponding abbre-
viations for the techniques (TMS, DBS, and tDCS). The 
Medical Subjects Headings and the Boolean operators AND/
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MeSH terms were as follows: 1) neuromodulation AND 
eating disorders; neuromodulation AND anorexia nervosa; 
neuromodulation AND bulimia nervosa; neuromodula-
tion AND binge eating disorder; neuromodulation AND 
obesity; 2) transcranial magnetic stimulation AND eating 
disorders; transcranial magnetic stimulation AND anorexia 
nervosa; transcranial magnetic stimulation AND bulimia 
nervosa; transcranial magnetic stimulation AND binge eating 
disorder; transcranial magnetic stimulation AND obesity; 
3) deep brain stimulation AND eating disorders; deep brain 
stimulation AND anorexia nervosa; deep brain stimula-
tion AND bulimia nervosa; deep brain stimulation AND 
binge eating disorder; deep brain stimulation AND obesity; 
4) transcranial direct current stimulation AND eating disor-
ders; transcranial direct current stimulation AND anorexia 
nervosa; transcranial direct current stimulation AND bulimia 
nervosa; transcranial direct current stimulation AND binge 
eating disorder; transcranial direct current stimulation AND 
obesity. Terms covering the most common specific eating 
disorders were used.
Other sources
As mentioned earlier, relevant studies were searched 
manually to identify studies published up to December 11, 
2017.
Selection of studies
Study selection was performed following the PRISMA pro-
cess (PRISMA 2009 Checklist).20 First, titles, abstracts, and 
keywords were examined to exclude those citations that were 
clearly irrelevant. After this first screening, the remaining 
articles were examined by the authors independently. In case 
of doubt, a decision about inclusion/exclusion of a particular 
study was made after discussion.
Data extraction
The following data were extracted from the included stud-
ies: authors, date of publication, population (including any 
information on types of ED), gender and age of participants, 
sample size, number of participants in each group, comorbid-
ity, types of interventions (TMS, DBS, and tDCS), length 
of the intervention period, measures, main outcomes, and 
others if necessary.
Assessment of methodological quality of 
included studies
Studies were evaluated by the authors following the Jadad 
scale.21 In this case, apart from the items related to bias 
control (randomization, quality of blinding, and reasons 
for withdrawal/dropouts) some others were considered: 
objectives, outcome measurements, well-defined inclusion/
exclusion criteria, clear description of intervention, descrip-
tion of adverse effects, and statistical analyses. A score of 2 
or above was accepted.
Data description
Table 1 shows the summary of main studies, and a narrative 
style was followed to better describe the results.
Results
Participants
The total number of participants in all trials was 562 (DBS: 
25; tDCS: 138; TMS: 399; range, 3–90; median, 23.5). As a 
result, 50% of the studies had samples of between 14 and 38 
participants. Participants were healthy controls and patients 
suffering from AN, BN, binge ED, and EDs not otherwise 
specified. In addition, patients with overweight, obesity, and 
frequent food craving were included.
interventions
In this study, interventions based on DBS, tDCS, and TMS 
were analyzed.
DBS
The study by Hayes et al analyzed possible differences 
between AN patients and healthy controls with respect to 
subcallosal cingulate cortex (SCC) connectivity.15 After 
undergoing DBS, AN patients (n=8) were studied by means 
of diffusion magnetic resonance imaging (dMRI) and 
deterministic multitensor tractography. AN patients also 
completed affect-related clinical assessments presurgically 
and 12 months postsurgery. As a result, they found higher 
(eg, left parieto-occipital cortices) and lower (eg, thalamus) 
connectivity in those with AN compared to controls; decrease 
in fractional anisotropy; and alterations in axial and radial 
diffusivities, the left fornix crus, anterior limb of the internal 
capsule (ALIC), right anterior cingulum, and left inferior 
fronto-occipital fasciculus. In addition, they observed cor-
relations between dMRI metrics and clinical assessments, 
such as low presurgical left fornix and right ALIC fractional 
anisotropy being related to post-DBS improvements in 
quality of life and depressive symptoms, respectively. The 
study revealed differences between SCC connectivity in AN 
compared to healthy controls. The authors suggested that 
differences in dMRI metrics along affect-related tracts may 
point to widespread structural abnormalities in AN.
Lipsman et al22 developed a prospective trial of SCC DBS 
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AN. Patients were followed up for 9 months after DBS 
activation. After 9 months, three of the six patients had 
achieved and maintained a body mass index (BMI) greater 
than their historical baselines. In four patients, DBS was 
associated with improvements in mood, anxiety, affective 
regulation, and AN-related obsessions and compulsions. 
Three patients showed improvements in quality of life after 
6 months of DBS. In addition, clinical benefits were associ-
ated with changes in cerebral glucose metabolism (PET scans 
at baseline and 6 months) that were consistent with a reversal 
of the abnormalities seen in the anterior cingulate, insula, 
and parietal lobe. The authors observed several adverse 
events such as pain, nausea, QT prolongation, air embolus, 
seizure, panic attack during surgery, and worsening mood. 
They also concluded that DBS might be able to change the 
natural history of AN, with the potential to improve clinical 
outcomes in some patients.
With respect to obesity, in the study by Whiting et al,23 
DBS of the lateral hypothalamic area (LHA) was used 
(2.5 years of stimulation), considering DBS as a potential 
treatment for intractable obesity. This study included three 
patients with intractable obesity (including failed bariatric 
surgery). These patients underwent bilateral implantation 
of LHA-DBS electrodes. In this case, no severe adverse 
effects were detected, and promising weight loss trends 
were observed when monopolar DBS stimulation applied 
via specific contacts found to increase the resting metabolic 
rate measured in a respiratory chamber. Across a wide spec-
trum of psychological and eating/weight-related measures, 
LHA DBS did not appear to create negative effects (anxiety/
tension, depression, cognitive dysfunction, emotional lability, 
and guardedness; binge eating episodes; cognitive restraint; 
hunger; body shape concerns; and quality of life).
tDCS
A total of six studies were considered, including patients 
with obesity, overweight, BN, and frequent food craving 
(n=138). No cases of AN were found in tDCS trials. All stud-
ies applied tDCS to DLPFC. The prefrontal cortex (PFC) and 
the dorsolateral sectors, in particular, play an important role 
in the organization and planning of behavior. It is possible 
that dysregulation of the left DLPFC in obesity and other 
eating disturbances might impair goal-oriented regulation of 
eating behavior and food choice, implicating that this region 
as a potential target for interventions.
Considering obesity, Gluck et al24 compared anodal/
sham vs cathodal/sham tDCS (a total of six sessions: 2 mA, 
40 minutes) aimed to the left DLPFC (LDLPFC). As a result, 
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Neuromodulation in eating disorders and obesity
fewer kcal from soda and fat, and had a greater % weight 
loss during anodal vs cathodal tDCS. With respect to side 
effects, the following were reported: scalp burn, tingling, 
skin redness, sleepiness, trouble concentrating, and mood 
change. The active group had a higher incidence of skin red-
ness compared to the sham group. This study supported that 
tDCS as a useful tool for potentially modifying the activity 
of the PFC and decreasing food intake.
Another study based on tDCS in obesity was developed 
by Grundeis et al,25 with a sample of 25 females. In this 
case, anodal, cathodal, and sham tDCS to the LDLPFC and 
contralateral frontal operculum were applied by means of 
single session. The authors hypothesized that tDCS would 
improve the ability to regulate the desire for visually pre-
sented foods and thereby reducing their consumption. All 
participants tolerated tDCS well. Reported side effects such 
as headache, dizziness, or burning sensations were only 
temporary and did not lead to premature discontinuation of 
the sessions. The findings of this study did not confirm an 
effect of tDCS, either on regulating/admitting the desire for 
foods or on calorie consumption.
Other studies based on tDCS have been focused on BN 
and frequent food craving. Kekic et al26 studied 39 bulimic 
patients by means of tDCS to the left/right DLPFC. In a 
randomized and counterbalanced procedure, participants 
received anode right/cathode left (AR/CL), anode left/cathode 
right (AL/CR), and sham. With respect to AR/CL tDCS, 
reduced ED cognitions were observed when compared to AL/
CR and sham tDCS. Both active conditions suppressed the 
self-reported urge to binge-eat and increased self-regulatory 
control during a temporal discounting (TD) task. Compared to 
sham stimulation, mood improved after AR/CL but not after 
AL/CR tDCS. Finally, the three tDCS sessions had compa-
rable effects on the wanting/liking of food and on bulimic 
behaviors during the 24 hours after stimulation. All sessions 
were associated with low levels of discomfort.
Three main studies have focused their experiments on 
frequent food craving. Fregni et al27 analyzed, in a random-
ized sham-controlled cross-over study, the effect of sham and 
active tDCS (AL/CR and AR/CL) of the DLPFC. Participants 
were exposed to food and also watched a movie of food 
associated with strong craving. Desire for food consumption 
was evaluated by VAS and by measuring food consumption 
before and after treatment. In addition, visual attention to 
food was explored using an eye tracking system. After sham 
stimulation, exposure to real food or food-related movie 
increased craving, whereas after AL/CR tDCS, the food-
related stimuli did not increase craving levels. Compared with 
sham stimulation, participants fixated food-related pictures 
less frequently after AR/CL tDCS and consumed less food 
after both active stimulation conditions. These changes were 
not related to mood changes after any type of tDCS treatment. 
The authors concluded that anodal tDCS of the DLPFC can 
suppress food craving. In another study, Kekic et al17 studied 
17 females who reported frequent food cravings ($1 per 
day, assessed by self-report questionnaire). The frequency 
of food craving and choice impulsivity (TD) were assessed. 
As a result, participants were exposed to food and a film 
of people eating, and food cravings and TD were assessed 
before and after active and sham stimulations. Craving for 
sweet but not savory foods was reduced following real tDCS. 
Participants who exhibited more reflective choice behavior 
were more susceptible to the anticraving effects of tDCS than 
those who displayed more impulsive choice behavior. No dif-
ferences were seen in TD or food consumption after real vs 
sham tDCS. These findings supported the efficacy of tDCS in 
temporarily lowering food cravings and identification of the 
moderating role of TD behavior. The study by Ljubisavljevic 
et al28 aimed to evaluate the utility of repeated tDCS of the 
right DLPFC cortex in changing food craving in young, 
healthy adults, and these changes may differ between normal 
and overweight participants. Participants were randomized 
into an “active” (5 days of real tDCS; 20 minutes, AR/CL 
montage, 2 mA with current density kept at 0.06 mA/cm2, 
1 minute ramp-up/ramp-down) and a “sham” group (1 day 
of real tDCS, on the first day – same parameters – followed 
by 4 days of sham tDCS). Food craving was assessed by the 
means of state/trait food craving questionnaires. The authors 
confirmed earlier findings showing that single session of 
tDCS had immediate effects in reducing food craving. Results 
also showed that repeated tDCS over the right DLPFC might 
increase the duration of its effects, which might be present 
30 days after the stimulation.
TMS
A total of 11 studies published between 2008 and 2017 were 
included. In these studies, 399 participants suffering from 
AN, BN, binge eating disorder (BED), eating disorders not 
otherwise specified (EDNOS), and obesity were studies. In 
nine of these studies, repetitive TMS (rTMS) was applied to 
the left DLPFC, whereas in one study, the authors used rTMS 
targeting the dorsomedial prefrontal cortex (DMPFC).
Considering AN, we found three studies based on the 
rTMS to the left DLPFC.29–31 In the first study, after applying 
20 rTMS trains, when compared to pre-rTMS, post-rTMS 
sensations of feeling fat and feeling full were decreased. 
There was also a significant decrease in anxiety.29 There were 
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task resulted in an increase in the urge to restrict and the 
sensation of feeling full. The authors concluded that rTMS 
appeared to be a safe and well-accepted brain modulation 
technique that might have an effect on core symptoms of AN 
such as feelings of fullness and fatness and anxiety. In the 
second study, a “study protocol” for a randomized controlled 
feasibility trial provided a foundation for the development of 
future large-scale RCTs.30 The study also proposed to include 
patients with an illness duration .3 years and a previous 
course of unsuccessful treatment who would receive 20 ses-
sions of either real or sham rTMS. Due to its rigorous meth-
odology, it is worth to include in this revision. In the third 
study,31 rTMS to the left DLPFC was applied in 49 patients. 
A food exposure task was administered before and after the 
procedure to elicit AN-related symptoms. Individuals who 
received real rTMS had reduced symptoms post-rTMS and 
at 24-hour follow-up, relative to those who received sham 
stimulation. In addition, real vs sham rTMS resulted in 
reduced rates of TD (more reflective choice behavior). Other 
psychopathology was not altered differentially following 
real/sham rTMS, and salivary cortisol concentrations were 
unchanged by stimulation. With respect to possible adverse 
effects, rTMS was safe, well tolerated, and considered an 
acceptable intervention.
With respect to BN, the study by Walpoth et al16 (2008) 
aimed to assess changes in binges and purges as well as in 
depressive and obsessive symptoms. Stimulation (to left 
DLPFC) was delivered for 3 weeks (3× for 5 days) with an 
intensity of 120% motor threshold using 20 Hz, in one ses-
sion a day. Ten trains of 10 seconds, with a train interval of 
60 seconds, were performed per session. To exclude patients 
highly responsive to placebo, all patients were first underwent 
a 1-week sham treatment. The authors reported that the aver-
age number of binges per day declined significantly between 
baseline and end of treatment in the two groups. There was 
no significant difference between sham and active stimula-
tion in terms of purge behavior, depressive, and obsessive 
symptoms over time. Gay et al32 obtained similar results and 
they reported that 10 sessions of high-frequency rTMS to the 
left DLPFC provided no greater benefit than placebo. In this 
study, a total of 47 patients were included, and no significant 
results were reported considering binge and vomiting epi-
sodes, specific variables of ED-related problems, and other 
psychopathological variables.
Along with BN, other studies have included patients 
with EDNOS, including three studies by van den Eynde 
et al.33–35 The first by van den Eynde et al33 included a total 
of 37 patients (20 BN and 17 EDNOS) who received one 
session of real (n=17) or sham rTMS (n=20) to the left 
DLPFC. In this case, the authors reported that compared 
with sham control, real rTMS was associated with decreased 
self-reported urge to eat and fewer binge-eating episodes 
over the 24 hours following stimulation. In the second study, 
38 patients were included to investigate cardiac safety of 
rTMS (to left DLPFC) in people with BN or EDNOS.34 
Cardiac vital signs were not affected by the administration of 
rTMS. In addition, there was no significant change in blood 
pressure or heart rate over time in either the real or sham 
rTMS condition. Finally, the third study included 33 patients 
with BN (n=16) and EDNOS (n=17).35 They received a single 
session of high-frequency (10 Hz) rTMS (real or sham) to 
the left DLPFC. In this study, a cognitive measure (Stroop 
color word task) was used to evaluate the effect of rTMS. The 
authors did not detect a difference between a single session 
of real and sham rTMS on the “interference score”, so rTMS 
had no immediate negative effect on selective attention, and 
no beneficial effect on performance of the Stroop task was 
observed. To explain these findings, the authors state that 
in contrast with the other outcome measures (food cravings 
and salivary cortisol concentrations) that showed significant 
effects of rTMS, the Stroop task was performed prior to the 
exposure to high-calorie foods. In this regard, it is possible 
that administering the Stroop task after the stressful event 
of exposure to food would have affected the results. The 
study Claudino et al36 included patients with BN (n=14) and 
EDNOS (n=8). They aimed to explore the effect of one ses-
sion of real high-frequency rTMS applied to the left DLPFC 
on food craving. Salivary cortisol concentrations following 
real rTMS were significantly lower compared with those 
following sham rTMS. In this study, there was also a trend 
for real rTMS to reduce food craving more than sham rTMS. 
The authors concluded that rTMS applied to the left DLPFC 
might alter hypothalamic–pituitary–adrenal axis activity in 
people with a bulimic disorder.
In other study, patients with AN (restrictive and binge-
purge subtypes), BN, and EDNOS were included.37 In this 
study, 20–30 sessions of rTMS were applied to the bilateral 
DMPFC, and all patients suffered from posttraumatic stress 
disorder (PTSD). Improvements in emotional regulation 
(emotional dysregulation is a central symptom in PTSD) 
accompanied improvements in PTSD symptoms. The authors 
highlighted that DMPFC is involved in aspects of emotion 
regulation and the inhibition of prepotent responses. In addi-
tion, the DMPFC is abnormally activated in PTSD patients 
during emotion regulation and appraisal, and PTSD-related 
emotion regulation deficits are related to altered connectivity 
of the medial PFC to the amygdala. The therapeutic effects of 
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Neuromodulation in eating disorders and obesity
Finally, Maranhão et al38 published a protocol to explore 
the effects of rTMS to the left DLPFC in patients with obe-
sity and BED. As noted above, with respect to a protocol by 
Bartholdy et al,30 due to the rigorous methodology, this study 
is worth to be included in this revision.
Some relevant characteristics of these 
studies
Participants included in the abovementioned studies con-
sidered an age range from 18 to 60 years. Only 45.83% of 
females were included. With respect to comorbidity, 16.66% 
of these studies included patients suffering from different 
mental disorders apart from specific EDs. In other cases, no 
specific psychopathology was detailed, but some of partici-
pants took antidepressants (12.5%). Some of these studies 
did not include a control group (16.66%). Generally, the 
authors compared the effect of real vs sham applications of 
neuromodulation techniques. The total number of sessions 
ranged between 1 and 30.
As it was mentioned, patients with all types of ED and 
overweight and obesity have been included to treat them 
using different techniques of neuromodulation. In some 
cases, patients suffered from refractory AN15 or intractable 
obesity (failed bariatric surgery),23 suffered from PTSD,36 
were considered chronic or with treatment resistance,22 (eg, 
without improvement under SSRI treatment),32 and showed 
a wide range of BMI.31 Healthy obese participants24,25 or 
healthy individuals who reported frequent food cravings17,27,28 
took part in the studies, and sometimes the illness duration 
showed a very wide range (eg, 4–528 months).26
In most of the included studies, the authors obtained some 
positive results, despite three studies reporting no significant 
improvement in binging and purging symptoms,32 no effects 
either on the ability to modulate the desire for visually pre-
sented foods or on calorie consumption,25 and no effects on 
selective attention after applying TMS.35
With respect to security of neuromodulation, the spe-
cific study by van den Eynde et al showed that there were 
no significant differences between groups in systolic or 
diastolic blood pressure or heart rate. In addition, there was 
no significant effect of time on any of these measures, and 
cardiac vital signs were not affected by the administration 
of TMS.34
Discussion
AN has been associated with brain changes such as reduced 
gray matter in fronto-limbic-striatal areas.39,40 Functional 
neuroimaging studies have suggested an overrepresentation 
of limbic drives (eg, from the insula and amygdala), together 
with the altered prefrontal activity.41 Alterations in dopamine, 
serotonin, and brain-derived neurotrophic factor (BDNF) 
have also been found in systems that have been implicated 
in reward processing, mood, and symptom plasticity among 
others.42,43 In this regard, a disease model for AN has sug-
gested altered interactions between “bottom-up” limbic 
drives (eg, reward and emotional processing) and “top-down” 
frontal lobe-mediated cognitive control.44–51 Specifically, 
hypoactivity of PFC regions during response inhibition and 
set-shifting tasks has been reported in AN.52–54 Reduced 
activity in the PFC might contribute to symptoms related to 
both impaired inhibitory control (ie, binge eating and purg-
ing) and poor cognitive flexibility (eg, compulsions such as 
body checking, exercising, and the obsessive concerns with 
eating, weight, and shape). The DLPFC has a key role in 
such self-regulatory control mechanisms and is a common 
target for neuromodulatory interventions in disorders of 
frontolimbic dysregulation.31
Functional imaging techniques, such as SPECT and 
PET, indicate left frontal cerebral hypometabolism in both 
depressive and bulimic patients. These changes of activity 
in the frontal area might be critical for eating control.55,56 
There are also evidences that food craving is associated 
with DLPFC activity, and previous studies have found that 
the capacity for self-control depends on DLPFC activity 
levels. DLPFC is a part of the dorsal cognitive frontostriatal 
circuitry (representing the major neural structure involved in 
executive functions, including self-regulatory control) and is 
also implicated in reward processing due to its anatomical/
functional connections with ventral limbic circuitry. Given 
the etiological relevance of these neurocognitive capacities 
in BN, manipulating the DLPFC might alleviate symptoms 
of the disorder.33,57
Apart from the role of DLPFC in both AN and BN, 
DMPFC seems to be more closely associated with emotional 
and behavioral self-control. In addition, the use of TMS on 
DMPFC has reported beneficial effects in major depres-
sion, binge eating and purging, and obsessive-compulsive 
disorder.58,59
Overall, there appear to be abnormalities in the use 
of cognitive reappraisal strategies, and brain systems that 
implement them contribute to disorders of eating behavior, 
including AN, BN, BED, obesity, and addiction. Across 
these disorders, there is often dysfunction in two major brain 
systems that also have key roles in cognitive reappraisal: one 
involving hypersensitivity to rewarding cues (eg, ventral 
striatum, amygdala, anterior insula, ventromedial prefrontal 
cortex [VMPFC], including orbitofrontal cortex) and the 






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





substance use (eg, anterior cingulate, lateral prefrontal cortex 
[LPFC], including DLPFC).60–62
Considering structural imaging, ED patients show reduc-
tions in gray matter volume in regions involved in reward, 
impulse control, and emotion regulation: the caudate nucleus, 
ventral striatum, anterior cingulate, and orbitofrontal cortex. 
Functional imaging reveals abnormal patterns of resting-
state connectivity in the default-mode network and other 
intrinsic brain networks incorporating the anterior cingulate 
and insula. ED patients also show abnormal ventral striatum 
activation in response to rewarding and aversive stimuli. 
Patients with BN usually show hyperactivity in medial 
frontal lobe regions during inhibition of prepotent actions 
and hypoactivity in response to food cues.63
Efficacy of neuromodulation in the treatment of different 
psychiatric disorders suggests that such techniques might 
be consider as another treatment tool in ED, especially 
in the context of modest success associated with current 
interventions.14 As stated by Van den Eynde et al,14 it is 
more appropriate to use the term neuromodulation than brain 
stimulation (thus referring not only to stimulation but also to 
inhibition or slow-downing brain functioning).
We have focused this review on an invasive technique 
(DBS) and two noninvasive procedures (tDCS and TMS). 
DBS aims to modulate the activity of dysfunctional brain 
circuits, and it has been used in different pathologies. DBS 
is an invasive but nonlesional procedure that exerts its effect 
both locally and remotely, across monosynaptically and 
polysynaptically linked networks.64,65 Generally, noninvasive 
techniques are feasible and acceptable as a treatment. These 
noninvasive procedures (eg, TMS and tDCS) avoid surgical 
interventions and base their action on magnetic fields that, 
after penetrating the skull, act on the brain. In 10 of 11 stud-
ies analyzed, which applied TMS, the technique was rTMS. 
In this case, magnetic fields are repeatedly applied, and this 
results in stimulation (high frequency, .1 Hz) or inhibition 
(low frequency, #1 Hz) of the underlying cortex. Most of 
the studies included in this review compared sham vs real 
rTMS. In the most common method for sham stimulation, the 
magnetic field is directed away from the brain.14,66 Generally, 
the period covered for this treatment ranged 1–30 sessions 
(the most common general period was 2–6 consecutive 
weeks; five sessions per week), and each session usually 
took 30–90 minutes.
In the studies by Hayes et al15 and Lipsman et al,22 based 
on DBS, SCC white matter was the chosen target given its 
role in affective regulation, its anatomic and physiologic 
links to relevant emotion and reward processing, and its 
relationship with abnormal serotonin receptor binding in ED 
patients. In addition, SCC is a widely connected hub contain-
ing appetitive- and aversive-responsive cells projecting to 
AN-affected regions, such as areas of the prefrontal, parietal 
and temporal cortices, insula, striatum, and amygdala. In the 
study by Whiting et al,23 the technique was applied to three 
patients with intractable obesity, and bilateral electrodes 
were implanted in the LHA. When this so-called feeding 
center is lesioned or stimulated (eg, by means of high fre-
quency electrical stimulation), both decreasing food intake 
and weight loss are observed. In this regard, it has been 
hypothesized that the hypothalamic nucleus might provide 
a target for modulating human energy balance in cases of 
refractory obesity.67
Only a total of 14 AN and three obese patients have been 
included in clinical studies based on DBS. Patients were 
heterogeneous, with different comorbidities and medications. 
In this regard, effects of DBS might be promising, but more 
studies are required.
Direct current stimulation (DCS) has been used in seven 
controlled studies. In these cases, DLPFC is the target due 
to the fact that food craving (as well as drug craving) is 
linked mostly with the left, right, or bilateral DLPFC (area 
in the PFC important for executive functioning), which 
is activated in response to cues that induce both food and 
drug cravings.68 The studies based on DCS have included 
138 patients with overweight and obesity, BN, and frequent 
food craving. Therefore, a deficiency in the prefrontal cortical 
inhibitory networks might contribute to the pathophysiology 
of disordered eating. The mechanisms by which DLPFC 
stimulation decreases cravings are unknown, although data 
suggest that reduced function in the right PFC may lead to 
overeating. It must be noted that noninvasive techniques of 
brain stimulation seem to suppress cravings even when the 
right DLPFC is inhibited and/or the left DLPFC is excited.17,69 
Generally, these studies have found a reduction in the calo-
rie intake per day, mood improvements, a reduction in ED 
cognitions, and a reduction in food craving. Nevertheless, 
the study by Grundeis et al25 does not support the notion 
of prefrontal/frontal DCS as a promising treatment option 
for obesity. Controversial findings due to methodological 
differences deserve more research in this field. In addition, 
the discrepancy between the study by Grundeis et al25 and 
other more positive findings24 demands further studies, for 
example, combining repetitive DCS instead of just one single 
session. In this regard, Ljubisavljevic et al, using repeated 
tDCS, reduced craving even 30 days after the intervention.28 
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strengthen the use of tDCS as an adjuvant intervention for 
overweight and obesity.
With respect to TMS, studies have included 90 patients 
with obesity and binge EDs, 206 patients with BN and 
EDNOS, and 49 AN patients. Again, DLPFC was the target. 
Therefore, reduced activity in the PFC might contribute to 
AN symptoms related to both impaired inhibitory control 
(ie, binge eating and purging) and poor cognitive flexibility 
(eg, compulsions such as body checking, exercising, and the 
obsessive pre-occupation with eating, weight and shape).31 
The DLPFC seems to have a key role in such self-regulatory 
control mechanisms and has been a common target for 
neuromodulatory interventions in disorders of frontolimbic 
dysregulation (depression, addictions, etc.). The psychophys-
iological mechanisms explaining the effects of rTMS in 
AN remain unclear. The DLPFC is involved in 1) emotion 
regulation, so that rTMS could improve maladaptive emotion 
regulation strategies in AN (ie, dietary restraint); 2) changes 
in synaptic plasticity, which is in accordance with reported 
increases in BDNF, modulation of extrastriatal dopamine, and 
bilateral DLPFC levels of 5-hydroxytryptamine (5-HT) after 
rTMS. These neural substrates have been implicated in the 
etiopathogenesis of AN. Furthermore, high-frequency rTMS 
to the DLPFC might remediate hypoactivity within prefrontal 
brain regions that has been associated with poor inhibitory 
control and impaired cognitive flexibility in AN.53,54,70–77 
Considering safety, tolerability, and acceptability, overall 
TMS could be considered an appropriate tool. In fact, 90% of 
people who had received real rTMS considered that if rTMS 
proved to be efficacious in treating AN, they would consider 
having it as a treatment (ie, 20 daily sessions).31
The use of TMS in bulimic symptoms is based on the fact 
that BN patients display aberrant patterns of PFC activity 
during a wide range of experimental tasks, and BN patients 
are assumed to have an addictive component.78 In this regard, 
it is possible that rTMS of the DLPFC could reduce overeat-
ing behaviors by reducing food cravings and by improving 
cognitive control.32
Generally, studies have found some different improve-
ments by means of TMS. Nevertheless, the study by Gay 
et al concluded that, despite being well tolerated, no signifi-
cant improvement in binging and purging symptoms was 
noted after 10 sessions of high-frequency rTMS to the left 
DLPFC.32 They proposed that future studies should consider 
methodological issues and alternative targets.
Despite methodological differences, small sample sizes 
(more than 50% of studies included less than 30 patients), 
and controversial results, neuromodulation seems to be a 
promising therapeutical approach in ED and obesity. Future 
studies should consider that above and beyond a specific diag-
nosis, other factors are relevant methodologically: medica-
tions taken, disease severity, comorbidity, evolution, history 
of previous treatments (and types of them), etc. Overall, crav-
ing has been reported to be reduced in several studies17,27,28,36 
as well as the urge to eat and binge episodes.16,26,33 In addition, 
reduction in calorie intake and higher percentage of weight 
loss have been reported.24 As a controversial result, Gay 
et al reported no significant improvement in binging and 
purging symptoms after rTMS. They suggested that 10 ses-
sions of high-frequency rTMS to the left DLPFC provided 
no greater benefit.32 In this regard, the number of sessions 
could be a relevant factor to be considered when applying 
neuromodulation techniques.
With respect to AN, core symptoms of this disorder and 
a decrease in fat-feeling and full-filling sensations have 
been observed in several neuromodulation studies.29,31 It is 
relevant that, in refractory AN, improvements in different 
psychological variables and quality of life have been shown. 
These findings undoubtedly highlight the promising role of 
neuromodulation in ED.22
Generally, patients who have been treated using DBS, 
tDCS, and TMS are heterogeneous with respect to symptoms 
and other aspects mentioned above. Often, different phases 
of disease (acute vs chronic) may be found, and results do 
not reveal a consistent pattern between structural alterations 
and behavior as it has been previously noted.15
ED and obesity are complex conditions that are difficult 
to treat given the underlying interplay between body homeo-
stasis, reward pathways, and affective/limbic circuitry. DBS 
offers a way to treat these patients despite some aspects that 
need to be refined (eg, exact stimulation parameters, brain 
targets, patient selection, timing and precise indications).79 
Overall, DBS seems to be a good option in patients with 
chronic, treatment-refractory AN.22 Noninvasive techniques 
are another promising way of treatment. Both tDCS and 
TMS show an excellent safety-feasibility profile and lack of 
severe side effects.79 Some authors state that tDCS has several 
practical advantages over TMS: it is portable, inexpensive, 
has a more safety-feasibility profile, and can be applied 
bilaterally.17 Clinically, the findings by Fregni et al27 extend 
the results of previous studies using TMS to inhibit craving 
as it suggests that excitability enhancing strategies of brain 
stimulation of the right hemisphere might be more effective 
in reducing food craving.
Despite not being “real” trials, two studies that were 
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study. Thus, the study by Bartholdy et al30 is a protocol, which 
includes a) a diagnosis based on Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition (DSM-5) crite-
ria; b) an illness duration .3 years and a previous course 
of unsuccessful treatment; c) a range of outcome variables 
(BMI, ED psychopathology, other psychopathology [eg, 
depression, anxiety], quality of life, neuropsychological 
processes [eg, self-regulation, attentional bias, and food 
choice behavior], neuroimaging measures [changes in brain 
structure or function], tolerability and acceptability of rTMS, 
and additional service utilization). The same protocol consid-
ers that acceptability and tolerability of the treatment would 
be assessed by means of semistructured interviews. Finally, 
feasibility would be evaluated through assessment of recruit-
ment and retention rates, acceptability of random allocation, 
blinding success (allocation concealment), completion of 
treatment sessions, and research assessments (baseline, 
posttreatment, and follow-up assessments). A relevant point 
of this protocol refers to the use of sham (placebo) vs real 
(active) high-frequency rTMS to the left DLPFC. The authors 
highlight the fact that no sham-controlled randomized control 
trials of therapeutic rTMS in AN have been conducted.30 The 
use of sham stimulation deserves some comments. Gener-
ally, sham stimulation approaches serve multiple purposes 
in neuromodulation research; they are used as both placebo 
and to control sensory side effects of neuromodulation. 
It must be noted that the concept of controlled conditions 
in neuromodulation research is not restricted to placebo and 
control of sensory side effects. In the light of this view, sham 
stimulation is limited, and its use has to be carefully balanced 
with other methodological considerations.80
The second study protocol aimed to be applied in patients 
with BED.38 Inclusion criteria for patients were as follows: 
1) meeting DSM-5 criteria for BED; 2) age ranging from 18 
to 55; 3) right-handed and able to write, read, and understand 
all elements of the study; 4) females; 5) BMI $35 kg/m2 and 
body weight #150 kg; and 6) laboratory blood tests within 
normal range at study enrollment. In this case, the current use 
of psychotropic drugs (except for antidepressants on a stable 
dose for at least 1 month), the current use of any antiobesity 
drug and medications that are known to reduce weight, and 
major psychiatric disorder requiring immediate treatment 
(eg, schizophrenia, bipolar disorder), substance dependence, 
and individuals currently receiving any psychological therapy 
for ED were exclusion criteria. With respect to outcome 
measures, primary (changes in binge eating episodes and urge 
to eat) and secondary (specific for BED and others such as 
impulsivity, depression, anxiety, and body shape) measures 
were considered along with anthropometric measures, 
several biomarkers, a cognitive evaluation, and neuroim-
aging. Finally, tolerability would be based on the number 
of adverse events reported and number of dropouts due to 
adverse events or other reasons. Safety would be measured 
based on the occurrence of serious adverse events such as 
seizures. The relevance of this protocol lies on the study of 
the rTMS effects on ED-related psychopathology linked to 
binge eating and craving. By using rTMS as a research tool, 
the authors extend the investigation of the examination of 
patterns of comorbidity, neurobiological, and neuropsycho-
logical underpinnings and of potential biomarkers.
Neuromodulation in ED seems to have clinical poten-
tials and therefore constitutes a promising area for further 
research. Developments in neuromodulation in ED will be 
linked to neuroimaging to identify potential stimulation 
targets and possible biomarkers of treatment response. To 
date, TMS and/or DCS are not the first-line treatment but 
perhaps will be. In the future, smaller sample sizes and very 
different methodologies should be avoided. Neuromodula-
tion techniques are in the experimental phase, and they are 
not an evidence-based treatment for ED.14
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